| Literature DB >> 35223337 |
Sarah A Wolfe1, Valentina Vozella1, Marisa Roberto1.
Abstract
PURPOSE: A growing body of evidence has implicated the endocannabinoid (eCB) system in the acute, chronic, and withdrawal effects of alcohol/ethanol on synaptic function. These eCB-mediated synaptic effects may contribute to the development of alcohol use disorder (AUD). Alcohol exposure causes neurobiological alterations similar to those elicited by chronic cannabinoid (CB) exposure. Like alcohol, cannabinoids alter many central processes, such as cognition, locomotion, synaptic transmission, and neurotransmitter release. There is a strong need to elucidate the effects of ethanol on the eCB system in different brain regions to understand the role of eCB signaling in AUD. SEARCHEntities:
Keywords: alcohol; alcohol use disorder; cannabinoid receptor; cannabis; cannabis use disorder; endocannabinoid; neurobiology; synaptic
Mesh:
Substances:
Year: 2022 PMID: 35223337 PMCID: PMC8843413 DOI: 10.35946/arcr.v42.1.03
Source DB: PubMed Journal: Alcohol Res ISSN: 2168-3492
Figure 1Summary schematic of endocannabinoid signaling in the synapse
A simplified description of the subcellular distribution of components of the endocannabinoid pathway is shown. Components include the major enzymes involved in regulating endocannabinoid levels (fatty acid amide hydrolase [FAAH], N-acyl phosphatidylethanolamine [NAPE], NAPE-specific phospholipase D [NAPE-PLD], monoacylglycerol lipase [MAGL], and diacylglycerol lipase-alpha [DAGL-alpha]); major endocannabinoids (anandamide [AEA], 2-arachidonylglycerol [2-AG]); lipid precursors and metabolites (arachidonic acid [AA], 2-acylglycerol [AG], diacylglycerol [DAG], and ethanolamine [EtNH2]); cannabinoid receptor 1 (CB1); neurotransmitter (NT); and major signaling cascade mediators downstream of CB1 activity (mitogen-activated protein kinases [MAPK], adenylate cyclase [AC], and calcium [Ca2+] signaling). Endocannabinoids signal in a retrograde manner to activate presynaptic CB1, which mediates signaling mechanisms that influence synaptic transmission and neurotransmitter release.
Acute Ethanol Exposure and ECB System Interaction, by Brain Region and Study
| Brain Region and Study | Ethanol Exposure | System | Species | Measure | Effect | Drug | Synaptic Activity | Effect |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Ferrer et al. (2007) | 4 g/kg, IP | Tissue | Wistar rats | AEA, 2-AG | Decrease | |||
| Rubio et al. (2009); | 24h liquid diet | Tissue | Sprague-Dawley rats | AEA, 2-AG | Decrease | |||
| Ferrer et al. (2007) | 4 g/kg, IP | Tissue | Wistar rats | FAAH activity | Decrease | |||
| Basavarajappa et al. (2008) | 30 and/or 60 min, 50 mM | Cultured neurons | C57BL/6J mice | AEA, 2-AG | Increase | |||
|
| ||||||||
| Roberto et al. (2004); | 5–10 min, 44 mM | Brain slice | Sprague-Dawley rats | GABA transmission | Increase | |||
| Roberto et al. (2010); | 5–10 min, 44 mM | Brain slice | Sprague-Dawley rats | WIN | Evoked and spontaneous GABA responses | Blockade | ||
| Roberto et al. (2010); | 5–10 min, 44 mM | Brain slice | Sprague-Dawley rats | Rimonabant, AM251 | Evoked and spontaneous GABAergic responses | Increase | ||
| Kirson et al. (2018) | 10–15 min, 44 mM | Brain slice | Wistar and msP rats | Glutamatergic transmission | Decrease | WIN AM251 | Evoked glutamatergic response (evoked EPSCs) | Further inhibition (males) and blockade of ethanol effect (Wistar females) with WIN |
|
| ||||||||
| Varodayan et al. (2017) | 5–10 min, 44 mM | Brain slice | Sprague-Dawley rats | GABAergic transmission | Increase | WIN | Spontaneous GABAergic transmission (GABA release) | Reduction with WIN |
| Perra et al. (2008) | 0.25–2.0g/kg, IV | Brain slice | Sprague-Dawley rats | Rimonabant, WIN chronic pretreatment | Inhibition of neuronal firing by ethanol | Reduction | ||
|
| ||||||||
| Ceccarini et al. (2013) | 4 g/kg, IP | Tissue | Wistar rats | AEA, CB1 binding | Increase | |||
| Caillé et al. (2007) | 30 min self-administration | Dialysate | Wistar rats | 2-AG | Increase | |||
| Hungund et al. (2003) | 1.5 g/kg, IP, 20–280 min | Dialysate | Mice | Dopamine release | Increase | CB1 knockout, Rimonabant | Dopamine release with ethanol | Inhibition |
| Di Chiara et al. (1988) | 0.25–2.5 g/kg, IP | Dialysate | Sprague-Dawley rats | Dopamine release | Increase | |||
|
| ||||||||
| Perra et al. (2005) | 0.5 g/kg, IV | Brain slice | Sprague-Dawley rats | Dopaminergic neurons firing | Increase | |||
|
| ||||||||
| Clarke et al. (2009) | 20 min, 20–50 mM | Brain slice | Wistar rats | eCB release | Inhibition and prevention of long-lasting neuronal disinhibition | |||
|
| ||||||||
| Kelm et al. (2007) | 5 min, 50–100 mM | Brain slice | Sprague-Dawley rats | Presynaptic GABA release | Increase | |||
| Kelm et al. (2008) | 5 min, 50–100 mM | Brain slice | Sprague-Dawley rats | WIN | Presynaptic GABA release (sIPSCs) | Inhibition |
Note: 2-AG, 2-arachidonoylglycerol; AEA, arachidonoylethanolamide (anandamide); CB1, cannabinoid receptor 1; eCB, endocannabinoid; EPSCs, excitatory postsynaptic currents; FAAH, fatty acid amide hydrolase; GABA, gamma-aminobutyric acid; IP, intraperitoneal; IV, intravenous; sIPSCs, spontaneous inhibitory postsynaptic currents; WIN, WIN 55,212-2.
Chronic Ethanol Exposure, Withdrawal, and ECB System Interaction, by Brain Region
| Brain Region and Study | Ethanol Exposure | System | Species | Measure | Effect | Drug | Synaptic Activity | Effect |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Ceccarini et al. (2013) | 7 days liquid diet (7% v/v) | Tissue | Wistar rats | CB1 binding | Reduction | |||
| Ceccarini et al. (2013) | 7 days liquid diet (7% v/v) + 2 weeks abstinence | Tissue | Wistar rats | CB1 binding | Recovery | |||
| Ortiz et al. (2004) | 52 days forced access | Tissue | Wistar rats | CB1 gene expression | Reduction | |||
| Mitrirattanakul et al. (2007) | 55 days oral intubation (6 g/kg daily) + 2 days withdrawal | Tissue | Sprague-Dawley rats | CB1 gene expression, CB1 protein | Reduction | |||
| Cippitelli et al. (2005) | 30 min daily sessions on a fixed ratio 1 schedule of reinforcement self-administration | Tissue | msP rats | CB1 gene expression | Reduction | |||
| González et al. (2002) | 15 days liquid diet (7% v/v) | Tissue | Wistar rats | CB1 binding and gene expression | No change | |||
| Mitrirattanakul et al. (2007) | 55 days oral intubation (6 g/kg daily) + 40 days withdrawal | Tissue | Sprague-Dawley rats | CB1 gene expression, CB1 protein, AEA, 2-AG | Increase | |||
|
| ||||||||
| Cippitelli et al. (2005) | 18 days self-administration (10% v/v in 30 min daily sessions on a fixed ratio 1 schedule reinforcement) | Brain slice | msP rats (and Wistar rats) | CB1 gene expression | Reduction | |||
| González et al. (2002) | 15 days liquid diet (7% v/v) | Tissue | Wistar rats | CB1 binding and gene expression | No change | |||
| Pava et al. (2014) | 4 days withdrawal after 10 days chronic ethanol | Slice cultures | C57BL6/J mice | WIN | Spontaneous GABA transmission | No change | ||
| Rimondini et al. (2002) | 7 weeks intermittent alcohol (17 h/day) | Tissue | Wistar rats | CB1 gene expression | Increase | |||
| Rimondini et al. (2002) | 3 weeks after 7 weeks of intermittent alcohol | Tissue | Wistar rats | CB1 gene expression | Recovery | |||
| Henricks et al. (2017) | Acute (1–4 days) withdrawal after 6 weeks chronic intermittent alcohol vapor | Tissue | Wistar rats | 2-AG | Reduction | |||
|
| ||||||||
| González et al. (2002) | 15 days liquid diet (7% v/v) | Tissue | Wistar rats | AEA | Increase | |||
| Serrano et al. (2012) | Withdrawal after 5 days per week for 3 weeks | Tissue | Wistar rats | CB1, MAGL gene expression | Reduction | |||
| Serrano et al. (2018) | 30 min on a fixed ratio 1 schedule self-administration | Dialysate | Wistar dependent rats | 2-AG | Decrease | |||
| Serrano et al. (2018); | 12 h withdrawal | Dialysate | Wistar dependent rats | AEA, 2-AG | Decrease | |||
| Varodayan et al. (2016) | 2–3 weeks CIE vapor for 14 h a day | Brain slice | Sprague-Dawley rats | WIN, AM251 | Spontaneous GABA transmission (GABA release) | CIE blunts WIN effect | ||
|
| ||||||||
| Robinson et al. (2016) | 10 days CIE vapor | Tissue; Brain slice | Sprague-Dawley rats | AEA | Increase | Glutamatergic transmission | Inhibition | |
| Robinson et al. (2016) | Rimonabant, AM251 | Glutamatergic transmission | Reverted ethanol-induced inhibition | |||||
| Henricks et al. (2017) | Acute (1–4 days) withdrawal after 6 weeks chronic intermittent alcohol vapor | Tissue | Wistar rats | AEA | Reduction | |||
| Varodayan et al. (2017) | 2–3 weeks CIE vapor for 14 h a day | Brain slice | Sprague-Dawley rats | WIN, AM251 | Spontaneous GABA transmission | CIE reduced WIN- and AM251-mediated effect | ||
|
| ||||||||
| Harlan et al. (2018) | 3 weeks withdrawal from CIE vapor | Brain slice | C57BL6/J mice | sIPSC frequency | Reduced | WIN, AM251 | eCB-mediated GABAA inhibition (evoked IPSCs) | Increase |
|
| ||||||||
| Cippitelli et al., (2005); | 30-min daily sessions on a fixed ratio 1 schedule of reinforcement self-administration | Tissue | Wistar rats | CB1 gene expression | Decrease | |||
| Vinod et al. (2006) | 72 h ethanol vapor (10–16 mg/l) | Tissue | Swiss Webster mice | CB1 density and activation | Decrease | |||
| Vinod et al. (2006) | 72 h ethanol vapor (10–16 mg/l) + 24 h withdrawal | Tissue | Swiss Webster mice | CB1 density and activation | Recovery | |||
| Vinod et al. (2012) | 70 days of two-bottle choice (24 h access/day) | Tissue | sP rats | CB1-mediated G protein coupling | Reduction | Rimonabant | CB1-mediated G protein coupling | Reversed |
| DePoy et al. (2013) | 2 weeks intermittent ethanol (16 h/day for 4 days per week) | Brain slice | C57BL6/J mice | 2-AG | Increase | CB1-mediated long-term depression | Abolition | |
|
| ||||||||
| Vinod et al. (2006) | 72 h ethanol vapor (10–16 mg/l) | Tissue | Swiss Webster mice | CB1 density and activation | Decrease | |||
| Vinod et al. (2006) | 72 h ethanol vapor (10–16 mg/l) + 24 h withdrawal | Tissue | Swiss Webster mice | CB1 density and activation | Recovery | |||
| Basavarajappa et al. (1999); | 72 h ethanol (100 mM) | Cultured cerebellar granular primary neurons and SK-N-SH (human cell line) | Sprague-Dawley rats | AEA, 2-AG synthesis | Increase | Rimonabant | Ethanol induced 2-AG synthesis | Inhibited |
| Basavarajappa et al. (1999); | 72 h ethanol (100–150 mM) | Cultured cerebellar granular primary neurons and SK-N-SH (human cell line) | Sprague-Dawley rats | NAPE-PLD activity | Increase | |||
| Basavarajappa et al. (2003) | 72 h ethanol (100–150 mM) | Cultured cerebellar granular primary neurons | Sprague-Dawley rats | AEA transport | Decrease | Rimonabant | AEA transport | No change |
Note: 2-AG, 2-arachidonoylglycerol; AEA, arachidonoylethanolamide (anandamide); CB1, cannabinoid receptor 1; CIE, chronic intermittent ethanol; FAAH, fatty acid amide hydrolase; GABA, gamma-aminobutyric acid; GABAA, gamma-aminobutyric acid type A receptor; MAGL, monoacylglycerol lipase; NAPE-PLD, N-acyl phosphatidylethanolamine–specific phospholipase D; sIPSC, spontaneous inhibitory postsynaptic current; WIN, WIN 55,212-2.